Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Convertible Debt (2016 - 2025)

Standard Biotools (LAB) has disclosed Convertible Debt for 12 consecutive years, with $299000.0 as the latest value for Q4 2025.

  • Quarterly Convertible Debt changed 0.0% to $299000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $299000.0 through Dec 2025, changed 0.0% year-over-year, with the annual reading at $299000.0 for FY2025, 0.0% changed from the prior year.
  • Convertible Debt for Q4 2025 was $299000.0 at Standard Biotools, roughly flat from $299000.0 in the prior quarter.
  • The five-year high for Convertible Debt was $55.0 million in Q3 2023, with the low at $299000.0 in Q1 2024.
  • Average Convertible Debt over 5 years is $30.1 million, with a median of $53.9 million recorded in 2021.
  • The sharpest move saw Convertible Debt grew 0.87% in 2023, then plummeted 99.46% in 2024.
  • Over 5 years, Convertible Debt stood at $54.2 million in 2021, then rose by 0.84% to $54.6 million in 2022, then plummeted by 98.96% to $569000.0 in 2023, then tumbled by 47.45% to $299000.0 in 2024, then changed by 0.0% to $299000.0 in 2025.
  • According to Business Quant data, Convertible Debt over the past three periods came in at $299000.0, $299000.0, and $299000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.